研究测试两种调理方案,在符合匹配供体同种异体移植资格的患者移植后使用环磷酰胺和甲氨蝶呤单次预防 GVHD (CY-MET-RIC)
随机 2 期研究在符合匹配供体同种异体移植资格的患者中测试移植后使用环磷酰胺和甲氨蝶呤单次预防移植物抗宿主病的两种调理方案
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH).
Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA donors, the use of cyclophosphamide (CY) administered in high doses at early post-transplant (PT) (=PTCY) (Days +3 and +4 or +5) has shown excellent control of acute and chronic GVH, even enabling the discontinuation of other immunosuppressive drugs administered after allo-CSH (ciclosporin, mycophenolate mofetyl (MMF) or Cellcept).
This step has already been taken in the context of allo-CSH with myeloablative conditioning (MAC), which is a minoritary conditioning in adults.
However, in the context of allo-CSH with reduced-intensity conditioning (RIC), which predominates in adults, this strategy seems insufficient to prevent the risk of GVHD.
The idea of reducing the use of immunosuppressants in the context of RIC/HLA-compatible transplants seems, however, still relevant, in order to reduce their adverse effects, improve patients' quality of life and enhance the reconstitution of the post-transplant immune system.
研究概览
地位
详细说明
For this reason, the investigators now wish to test the administration of a combination of a high dose of early post-transplant CY (PTCY) and methotrexate (MTX) on days (D) D+1, D+4, D+6, D+11 (doses already performed in MAC transplant prophylaxis), with anti-lymphocyte serum (ALS) with RIC conditioning, without ciclosporin or MMF.
The investigators hypothesize that administration of this PTCY+MTX combination will enable immunosuppressive drugs to be discontinued as early as D+11 post-transplant, compared with the usual average of 3 to 4 months.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Amandine LE BOURGEOIS, MD
- 电话号码:+33 02 40 08 32 71
- 邮箱:amandine.lebourgeois@chu-nantes.fr
学习地点
-
-
-
Angers、法国
- 招聘中
- CHU Angers
-
接触:
- Sylvain THEPOT, MD
- 电话号码:+33 0241354482
- 邮箱:sylvain.thepot@chu-angers.fr
-
Brest、法国
- 招聘中
- CHU Brest
-
接触:
- Marie-Anne COUTURIER, MD
- 电话号码:+33 0298223765
- 邮箱:marie-anne.couturier@chu-brest.fr
-
Nantes、法国
- 招聘中
- CHU Nantes
-
接触:
- Amandine LE BOURGEOIS, MD
- 电话号码:+33 0240083271
- 邮箱:amandine.lebourgeois@chu-nantes.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age: ≥ 18 and ≤ 70 years old
- Patient with hematologic malignancy
- Indication for HSC allograft with attenuated conditioning
- Pluripotent stem cell (PSC) engraftment
- Availability of a 10/10 familial or non-familial HLA compatible donor
- Consent to the protocol
- ECOG <=2
- Woman of childbearing age with negative pregnancy test and on highly effective contraception during treatment and for a period of 12 months after stopping MTX and CY
- Man of childbearing age with highly effective contraception during treatment and for a period of 6 months after stopping MTX and CY and a period of 12 months after stopping MTX and CY if TBF conditioning regimen arm
- Negative Hepatitis B, C, HIV serologies
- Social security affiliation
Exclusion Criteria:
- History of allograft
- Patient eligible for myeloablative conditioning (MAC)
- Bone marrow transplant
- Other progressive cancerous disease, or antecedent of cancer in the last five years, with the exception of a carcinoma of the skin or a carcinoma in situ of the uterine cole treated and in remission.
- Progressive psychiatric condition
- Pregnant or breastfeeding woman,
- Woman or man of childbearing age with lack of effective contraception
- Serious and uncontrolled concomitant infection
- Cardiac: systolic ejection fraction < 50% by transthoracic ultrasound or by isotopic method (isotope gamma angiography), NYHA II, III or IV heart failure, active rhythmic, valvular or ischemic heart disease or anteriority
- Respiratory with EFR: DLCOc <40% of theoretical
- Renal: creatinine clearance < 50 ml/min (assessment with MDRD method)
- Urological: active urinary tract infection, history of acute urothelial toxicity due to cytotoxic chemotherapy or radiotherapy, known obstruction of urinary flow, pre-existing hemorrhagic cystitis
- Hepatic: transaminases greater than 5 times normal or bilirubin greater than 2 times normal
- Person protected by law (major under guardianship, curatorship or legal protection)
- Vaccination against yellow fever in the last year
- Known or suspected hypersensitivity to rabbit proteins as well as to the active substance and excipients of all investigational and ancillary drugs administered during the study,
- Contraindication to any of the investigational or adjuvant drugs administered during the study
- Patient not speaking French
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:(CLO)-BALTIMORE
BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY |
15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
其他名称:
50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
其他名称:
Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
其他名称:
Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0) Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
其他名称:
2 grays on Day-1 before graft (=Day0)
其他名称:
High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
其他名称:
Graft nuclear cells CD3+ cells if needed after transplantation DLI with CD3+ if relapse after transplantation or in prevention of relapse
其他名称:
Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0) Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
其他名称:
|
|
有源比较器:TBF
Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY |
15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
其他名称:
50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
其他名称:
Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
其他名称:
Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
其他名称:
High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
其他名称:
Graft nuclear cells CD3+ cells if needed after transplantation DLI with CD3+ if relapse after transplantation or in prevention of relapse
其他名称:
Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
其他名称:
Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0) Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of grade 3-4 acute GVHD following allo-CSH for all patients and for each conditioning group (Baltimore and TBF).
大体时间:Post-transplant through study completion, an average of 1 year
|
Estimation of the incidence of grade 3 and 4 acute GVHD following allo-CSH (excluding post-DLI* acute GVHD) according to Mount Sinai criteria. |
Post-transplant through study completion, an average of 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of engraftment
大体时间:Month 1 post-transplant
|
Engraftment assessed on hematological reconstitution (number of days of aplasia with PNN <0.5 G/L and platelets < 20 G/L, number of platelet and red cell concentrate transfusions) |
Month 1 post-transplant
|
|
Overall survival (OS)
大体时间:Post-transplant through study completion, an average of 1 year
|
survival between day 0 of transplantation and date of death or last follow-up |
Post-transplant through study completion, an average of 1 year
|
|
Disease-free survival (DFS)
大体时间:Post-transplant through study completion, an average of 1 year
|
survival between day 0 of transplantation and date of relapse, death or last follow-up |
Post-transplant through study completion, an average of 1 year
|
|
GVHD and relapse-free survival (GRFS)
大体时间:Post-transplant through study completion, an average of 1 year
|
relapse-free survival without grade 3-4 acute GVHD or chronic GVHD requiring systemic treatment |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of acute GVHD grade 2-4
大体时间:Post-transplant through study completion, an average of 1 year
|
Acute GVH grade 2-4 according to Mount Sinai criteria |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of chronic GVHD
大体时间:From month 3 post-transplant through study completion, an average of 1 year
|
Chronic GVHD according to NCI criteria |
From month 3 post-transplant through study completion, an average of 1 year
|
|
Incidence of corticoresistant acute GVHD
大体时间:Post-transplant through study completion, an average of 1 year
|
Acute corticoresistant GVHD according to the criteria of Mohty et al. defined by :
|
Post-transplant through study completion, an average of 1 year
|
|
Incidence of non-relapse mortality (NRM)
大体时间:Post-transplant through study completion, an average of 1 year
|
any death unrelated to relapse or disease progression |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of relapse
大体时间:Post-transplant through study completion, an average of 1 year
|
any documented disease recurrence |
Post-transplant through study completion, an average of 1 year
|
|
Chimerism
大体时间:At Month1, Month2, Month3, Month6, Month12 post-transplant
|
Total donor or mixed chimerism. Total donor chimerism = result >95% donor CD3+ cells. Mixed chimerism = result >5% and <95% donor CD3+ cells. |
At Month1, Month2, Month3, Month6, Month12 post-transplant
|
|
Immune reconstitution
大体时间:At Month3, Month6, Month9, Month12 post-transplant
|
T, NK, B lymphocytes and monocytes |
At Month3, Month6, Month9, Month12 post-transplant
|
|
Grade 3 and 4 post-transplant adverse events
大体时间:Post-transplant through study completion, an average of 1 year
|
Grade 3 and 4 post-transplant adverse events (dates of occurrence) (NCI CTCAE criteria, version number 5) |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of viral, bacteriological, fungal and parasitic infections
大体时间:Post-transplant through study completion, an average of 1 year
|
Infections: viral (CMV, EBV, BKV, adenovirus), bacteriological, fungal and parasitic |
Post-transplant through study completion, an average of 1 year
|
合作者和调查者
调查人员
- 首席研究员:Marie-Anne COUTURIER, MD、University Hospital, Brest
- 首席研究员:Sylvain THEPOT, MD、University Hospital, Angers
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- RC23_0286
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.